The National Institutes of Health (NIH) announced on June 20, 2020, that the ORCHID study evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with COVID-19 has been stopped.
A data and safety monitoring board (DSMB) met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19. After its fourth interim analysis, the DSMB recommended to the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, to stop the study. NHLBI halted the trial immediately.
The ORCHID study was a multicenter blinded placebo-controlled randomized clinical trial being conducted by the Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network of NHLBI. The data from this study indicate that this drug provided no additional benefit compared with placebo control for the treatment of COVID-19 in hospitalized patients.
National Institutes of Health (NIH). NIH halts clinical trial of hydroxychloroquine [media advisory]. June 20, 2020. Available at: click here. Accessed June 22, 2020.